180 related articles for article (PubMed ID: 31097113)
21. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma].
Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775
[No Abstract] [Full Text] [Related]
22. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
23. Prominent Papillary Growth Pattern and Severe Nuclear Pleomorphism Induced by Neoadjuvant Chemotherapy in Ovarian Mucinous Carcinoma: Potential for Misdiagnosis as High-grade Serous Carcinoma.
Kwon HJ; Song SY; Kim HS
Anticancer Res; 2021 Mar; 41(3):1579-1586. PubMed ID: 33788752
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV
Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643
[TBL] [Abstract][Full Text] [Related]
25. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
Morency E; Leitao MM; Soslow RA
Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
[TBL] [Abstract][Full Text] [Related]
27. Serous tubal intraepithelial carcinoma, chronic fallopian tube injury, and serous carcinoma development.
Malmberg K; Klynning C; Flöter-Rådestad A; Carlson JW
Virchows Arch; 2016 Jun; 468(6):707-13. PubMed ID: 27003156
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
Chung YS; Lee JY; Kim HS; Nam EJ; Kim SW; Kim YT
Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699
[TBL] [Abstract][Full Text] [Related]
29. Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases.
Schneider S; Heikaus S; Harter P; Heitz F; Grimm C; Ataseven B; Prader S; Kurzeder C; Ebel T; Traut A; du Bois A
Int J Gynecol Cancer; 2017 Mar; 27(3):444-451. PubMed ID: 28187099
[TBL] [Abstract][Full Text] [Related]
30. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas.
Soong TR; Howitt BE; Miron A; Horowitz NS; Campbell F; Feltmate CM; Muto MG; Berkowitz RS; Nucci MR; Xian W; Crum CP
J Pathol; 2018 Nov; 246(3):344-351. PubMed ID: 30043522
[TBL] [Abstract][Full Text] [Related]
31. High-grade serous carcinoma of tubo-ovarian origin: recent developments.
Singh N; McCluggage WG; Gilks CB
Histopathology; 2017 Sep; 71(3):339-356. PubMed ID: 28477361
[TBL] [Abstract][Full Text] [Related]
32. Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: diagnostic pitfalls and clues to improve recognition of tumor origin.
Bagby C; Ronnett BM; Yemelyanova A; Maleki Z; Kuhn E; Vang R
Int J Gynecol Pathol; 2013 Sep; 32(5):433-43. PubMed ID: 23896706
[TBL] [Abstract][Full Text] [Related]
33. Detection of serous precursor lesions in resected fallopian tubes from patients with benign diseases and a relatively low risk for ovarian cancer.
Nishida N; Murakami F; Higaki K
Pathol Int; 2016 Jun; 66(6):337-42. PubMed ID: 27250113
[TBL] [Abstract][Full Text] [Related]
34. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
35. The role of the fallopian tube in ovarian cancer.
Tone AA; Salvador S; Finlayson SJ; Tinker AV; Kwon JS; Lee CH; Cohen T; Ehlen T; Lee M; Carey MS; Heywood M; Pike J; Hoskins PJ; Stuart GC; Swenerton KD; Huntsman DG; Gilks CB; Miller DM; McAlpine JN
Clin Adv Hematol Oncol; 2012 May; 10(5):296-306. PubMed ID: 22706539
[TBL] [Abstract][Full Text] [Related]
36. Serous tubal intraepithelial carcinoma localizes to the tubal-peritoneal junction: a pivotal clue to the site of origin of extrauterine high-grade serous carcinoma (ovarian cancer).
Seidman JD
Int J Gynecol Pathol; 2015 Mar; 34(2):112-20. PubMed ID: 25675178
[TBL] [Abstract][Full Text] [Related]
37. Low-grade serous ovarian cancer: a unique disease.
Schmeler KM; Gershenson DM
Curr Oncol Rep; 2008 Nov; 10(6):519-23. PubMed ID: 18928667
[TBL] [Abstract][Full Text] [Related]
38.
Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
[TBL] [Abstract][Full Text] [Related]
39. Tumour morphology after neoadjuvant chemotherapy as a predictor of survival in serous ovarian cancer: an experience from a tertiary care centre in India.
Khandakar B; Kumar L; Kumar S; Gupta SD; Kalaivani M; Iyer V; Mathur SR
Malays J Pathol; 2015 Aug; 37(2):115-21. PubMed ID: 26277668
[TBL] [Abstract][Full Text] [Related]
40. Adopting a Uniform Approach to Site Assignment in Tubo-Ovarian High-Grade Serous Carcinoma: The Time has Come.
Singh N; Gilks CB; Hirshowitz L; Wilkinson N; McCluggage WG
Int J Gynecol Pathol; 2016 May; 35(3):230-7. PubMed ID: 26977579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
